- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04361240
Cardiotoxicity in Breast Cancer Patients Treated With Proton or Photon Radiotherapy: A RadComp Companion Study
April 9, 2024 updated by: Abramson Cancer Center at Penn Medicine
This is a companion study to the "Pragmatic Randomized Trial of Proton vs Photon Therapy for Patients with non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RadComp) Consortium Trial" (NCT02603341).
The investigators will collect cardiovascular (CV) biomarkers and echocardiograms prior to, during, and for up to 1 year following radiation for a subset of patients enrolled on RadComp and to evaluate the impact of proton vs photon radiation therapy (RT) on CV function and structure.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
The study population of the companion study will consist of newly enrolled RadComp trial participants.
Patients on this ancillary will be consented prior to RadComp randomization to decrease the bias secondary to RT type and enhance internal validity.
The study will define the early changes in biomarkers, imaging measures, and RT dose volume metrics and long-term (5-10 year) CV clinical outcomes using the RadComp parent study's infrastructure for clinical data collection and long-term follow-up.
Blood samples, echocardiograms, and questionnaires are obtained at baseline (between end of chemotherapy and start of RT), immediately after the end of RT, and at 6 months and 12 months after the end of RT.
An additional blood sample will be collected at 4 weeks after the start of RT.
Clinical, demographic, and patient reported outcomes data are collected as part of the RadComp parent study.
In addition to data collected by RadComp, we will collect a limited set of clinical data and two additional quality of life instruments for the companion study.
Study Type
Observational
Enrollment (Estimated)
175
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama
-
-
Illinois
-
Warrenville, Illinois, United States, 60555
- Northwestern Medicine
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Abramson Cancer Center at University of Pennsylvania
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Sampling Method
Non-Probability Sample
Study Population
Patients eligible for and enrolling on the RadComp trial at participating RadComp sites will be approached for the companion cohort.
Description
Inclusion Criteria:
- Consented to RadComp
- Willing and able to provide written consent
Exclusion Criteria:
- Knowledge of randomization on RadComp prior to enrollment on companion study
- Non-diagnostic echocardiography windows as assessed on local read.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Ancillary Cohort
No Intervention: Subjects will be followed before, during and for up to 1 year after radiation with echocardiogram, blood draw, and symptoms and activity survey.
|
Assignment to proton vs photon by randomization on RadComp parent study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Left ventricular ejection fraction (LVEF)
Time Frame: 14 months
|
Change in echocardiography derived LVEF from baseline
|
14 months
|
Right Ventricular (RV) Fractional Area Change (FAC)
Time Frame: 14 months
|
Change in echocardiography derived RV FAC from baseline
|
14 months
|
Circulating N-terminal pro B-type natriuretic peptide (NTproBNP)
Time Frame: 14 months
|
Change in NTproBNP levels from baseline
|
14 months
|
Circulating Placental Growth Factor (PIGF)
Time Frame: 14 months
|
Change in PIGF levels from baseline
|
14 months
|
Circulating Growth Differentiation Factor-15 (GDF-15)
Time Frame: 14 months
|
Change in GDF-15 levels from baseline
|
14 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LV systolic strain
Time Frame: 14 months
|
Change in 2D echocardiography derived LV global longitudinal strain and circumferential strain from baseline
|
14 months
|
Echocardiography derived Ventricular Arterial Coupling Measurement
Time Frame: 14 months
|
Change from baseline in ventricular arterial coupling as defined by end systolic elastance divided by effective arterial elastance
|
14 months
|
Diastolic function (E/e')
Time Frame: 14 months
|
Change in E/e' from baseline as measured by echocardiogram
|
14 months
|
Circulating Troponin T(TnT)
Time Frame: 14 months
|
Change in high-sensitivity TnT levels from baseline
|
14 months
|
Circulating high-sensitivity C-Reactive Protein (hsCRP)
Time Frame: 14 months
|
Change in hsCRP levels from baseline
|
14 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
3D LVEF
Time Frame: 14 months
|
Change in 3d echocardiography derived LVEF from baseline
|
14 months
|
3D LV systolic strain
Time Frame: 14 months
|
Change in 3D echocardiography derived longitudinal and circumferential strain from baseline
|
14 months
|
LV Twist and Torsion
Time Frame: 14 months
|
Change in 3D echocardiography derived measures of LV twist and torsion from baseline
|
14 months
|
Patient Reported Outcomes (PRO) Common Terms and Criteria for Adverse Events (CTCAE)
Time Frame: 14 months
|
Incidence and severity of PRO CTCAEs
|
14 months
|
Incidence of major cardiovascular events (MCE)
Time Frame: 10 years
|
Collected, defined, and adjudicated by the RadComp study team
|
10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Bonnie Ky, MD, MSCE, University of Pennsylvania
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2020
Primary Completion (Estimated)
April 1, 2025
Study Completion (Estimated)
April 1, 2025
Study Registration Dates
First Submitted
April 6, 2020
First Submitted That Met QC Criteria
April 23, 2020
First Posted (Actual)
April 24, 2020
Study Record Updates
Last Update Posted (Actual)
April 10, 2024
Last Update Submitted That Met QC Criteria
April 9, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UPCC 17119
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
Participants may opt in to allowing data and/or banked samples to be used for future research and shared with other researchers.
A detailed plan for sharing IPD will be finalized at a later date, and may depend in part on how many participants elect this option.
Additional supporting information may be shared, including the study protocol and informed consent form.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Proton vs Photon Radiation
-
Massachusetts General HospitalCompletedMesenchymal TumorUnited States
-
Danish Breast Cancer Cooperative GroupRecruitingEarly Breast Cancer | Radiation Associated Cardiac FailureDenmark
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institute of Dental and Craniofacial...Active, not recruitingStage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7United States
-
University of FloridaCompleted
-
Massachusetts General HospitalNational Cancer Institute (NCI); American Society of Clinical OncologyRecruitingMyocardial Fibrosis | Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIIUnited States
-
Memorial Sloan Kettering Cancer CenterMayo ClinicRecruitingHead and Neck CancerUnited States
-
Emory UniversityNational Cancer Institute (NCI)RecruitingSchwannoma | Grade III Meningioma | Intracranial Neoplasm | Nerve Sheath Neoplasm | Grade II Meningioma | Grade I Meningioma | Pituitary Gland AdenomaUnited States
-
Odense University HospitalNot yet recruitingFrailty | Non-small Cell Lung Cancer Stage III | Radiotherapy Side Effect
-
Abramson Cancer Center at Penn MedicinePatient-Centered Outcomes Research InstituteActive, not recruiting
-
Loma Linda UniversityEnrolling by invitation